BioVie Presents Data on Bezisterim in Parkinson’s Disease at the 2026 American Neurological Association Annual Meeting
BioVie presented Phase 2b SUNRISE-PD data on bezisterim in early Parkinson's disease at the American Neurological Association annual meeting, with the abstract published in Annals of Neurology. In the prespecified high-inflammation subgroup (roughly half of the 57-patient trial), bezisterim showed statistically significant improvements on MDS-UPDRS motor and non-motor scores versus placebo, and the Composite Benefit Score showed a large treatment effect (Cohen's d = -1.61; p=0.0004). Bezisterim was also well tolerated, with fewer treatment-emergent adverse events than placebo and no severe or serious adverse events.
Key figures
- Drug Name
- bezisterim (NE3107)
- Phase Of Trial
- Phase 2b
- Teae rate
- 39.3% bezisterim vs 51.7% placebo
- Trial name
- SUNRISE-PD
- Cbs p value
- p=0.0004
- Cbs cohens d
- -1.61
- Patients randomized
- 57
- Treatment period weeks
- 12
- Worsening relative risk
- 0.30 (14% vs 46%)
- Clinically meaningful improvement
- 25% bezisterim vs 4% placebo (6.25-fold)
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.